Cardiometabolic disease therapies
Discovering new approaches for treating hyperlipidemia using an induced pluripotent stem cell based platform.
This joint laboratory will discover potentially pathways for modulation of LDL levels in blood and the management of hyperlipidemia.
Cardiovascular diseases (CVDs) are major causes of mortality and morbidity worldwide. This project aimed to identify therapeutic targets for drug discovery in cardiometabolic diseases as well as discover new approaches for treating hyperlipidaemia using an induced pluripotent stem cell based platform. This included establishing genotype-phenotype correlations in patients with hyperlipidaemia by analysing the HKU’s own mega data of single nucleotide polymorphisms (SNPs) for the Hong Kong population, and correcting certain mutations or polymorphisms to test the feasibility and specificity of targeting the mutations in certain genes. Utilising induced pluripotent stem cells (iPSCs) derived from patients with extreme cardiometabolic phenotypes allowed the researchers to investigate the effects of rare genetic variants and research how to correct these mutations using CRISPR/Cas9 technology.
-
Original project funded for three years from 2016
Key topics
- Cardiometabolic disorders
- Genetic variants
- iPSC technology
- Therapeutic targets
Directors
Hung-Fat Tse
Chair professor; Co-director, Hong Kong-Guangdong Stem Cell and Regenarative Medicine Research Centre Situation unknown
Guanjin Pan
Professor at the CAS Institutes of Biomedicine and Health, Guangzhou
Other projects
Adult stem cell regeneration
Original project funded for three years from 2024
Chiral electronic materials
Original project funded for three years from 2024
Extreme temperature electronics
Original project funded for three years from 2022
Glioma drug resistance
Original project funded for three years from 2024
Stay in the loop!
Subscribe to keep up with the latest from Croucher Foundation.